VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- ViewsML, a company building the computational layer for biomarker discovery by transforming tissue analysis from a lab process into software, today announced the completion of an oversubscribed $4.9M seed funding round led by Wittington Ventures. Additionally, new investors Continuum Health Ventures and Mayo Clinic contributed alongside repeat investors RiSC Capital, Debiopharm, WUTIF, Defined, and e-Fund.

This funding reflects the investment community's recognition of the significance of ViewsML's technology and its development of the world's first virtual biomarker library using artificial intelligence to generate per-cell biomarker spatial insights from pathology images without the need for laboratory staining.

As demand for scalable, high-resolution biomarker data grows across drug development and diagnostics, traditional staining workflows have become a critical bottleneck. Virtual biomarker staining represents a fundamental shift in how immunostaining is generated and analyzed, enabling an entirely new paradigm for assay development. ViewsML is leading this transformation through a scalable computational platform that converts a traditionally lab-bound process into software via its ...